Michael McNamara, DO
Psychiatry · Manchester, NHNPI 1861477259
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $572,698 of the $754,107 with a category attached, or 75.9%. 21 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 28.9% of the total. 2025 is the largest year on record at $255,678, 3.4 times the $75,285 reported in 2019. Among psychiatry clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,305 payments — averaging $577.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$218K
- Neurocrine Biosciences, Inc.$150K
- E.r. Squibb & Sons, L.L.C.$100K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$81K
- Alkermes, Inc.$69K
- Teva Pharmaceuticals USA, Inc.$49K
- plus $87K from 15 others
Across 2 payments — averaging $1625.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$3K
What the payments were for
- Consulting fees$77,97110%
- Speaking & faculty fees$572,69876%
- Travel & lodging$69,8219%
- Food & beverage$33,4594%
- Education$1580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 244 | $217,774 |
| Neurocrine Biosciences, Inc. | 186 | $149,895 |
| E.r. Squibb & Sons, L.L.C. | 103 | $100,136 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 92 | $81,420 |
| Alkermes, Inc. | 153 | $69,001 |
| Teva Pharmaceuticals USA, Inc. | 64 | $49,247 |
| AbbVie(2 entities) | 245 | $42,461 |
| Axsome Therapeutics, Inc. | 30 | $24,254 |
| Johnson & Johnson | 81 | $15,424 |
| Vanda Pharmaceuticals Inc. | 78 | $1,665 |
| Indivior Inc. | 4 | $1,281 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $653 |
| Sage Therapeutics, LLC | 4 | $285 |
| Sunovion Pharmaceuticals Inc. | 8 | $191 |
| Avanir Pharmaceuticals, Inc. | 1 | $125 |
| Novo Nordisk | 1 | $124 |
| Janssen Scientific Affairs, LLC | 1 | $61 |
| Amgen | 1 | $41 |
| Luye Pharma (USA) Ltd. | 1 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$239,151
- REXULTI$158,905
- INGREZZA$145,213
- CAPLYTA$79,217
- COBENFY$70,139
- ABILIFY MAINTENA$57,781
- UZEDY$41,322
- VRAYLAR$39,099
- Auvelity$23,346
- ABILIFY ASIMTUFII$20,653
- INVEGA SUSTENNA$13,192
- INVEGA TRINZA$12,821
- VIVITROL$5,944
- AUSTEDO$3,679
- Austedo XR$3,165
- PERSERIS$1,186
- SPRAVATO$1,028
- NUEDEXTA$125
- Wegovy$124
- Fanapt$116
How this compares
$754,107 in reported general payments places this provider in the 95th percentile of 166 psychiatry providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 49 | $170,204 |
| Austedo XrDeutetrabenazine | 39 | $165,279 |
| LybalviOlanzapine/Samidorphan Malate | 100 | $158,156 |
| VraylarCariprazine Hcl | 108 | $150,690 |
| IngrezzaValbenazine Tosylate | 21 | $140,156 |
| CaplytaLumateperone Tosylate | 75 | $119,405 |
| UzedyRisperidone | 34 | $111,564 |
| Abilify AsimtufiiAripiprazole | 13 | $78,595 |
| Abilify MaintenaAripiprazole | 27 | $78,220 |
| FanaptIloperidone | 34 | $74,246 |
| AuvelityDextromethorphan Hbr/Bupropion | 67 | $67,613 |
| AristadaAripiprazole Lauroxil | 18 | $56,834 |
| RexultiBrexpiprazole | 32 | $50,721 |
| Risperdal ConstaRisperidone Microspheres | 24 | $22,959 |
| Clozapine | 251 | $13,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $49,247 | $276,84473 claims |
| Alkermes, Inc.Lybalvi, Aristada | $69,001 | $214,989118 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena, Rexulti | $217,774 | $207,53672 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $15,424 | $193,16373 claims |
| AbbVieVraylar | $42,461 | $150,690108 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $149,895 | $140,15621 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $81,420 | $119,40575 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,665 | $74,24634 claims |
| Axsome Therapeutics, Inc.Auvelity | $24,254 | $67,61367 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 psychiatry providers in New Hampshire.
Other psychiatry in Manchester
- Janet CarellaManchester$82K
- Quentin TurnbullManchester$25K
- Ashwini SaxenaManchester$1K
- Akash VadaliaManchester$702
- Almos NagyManchester$648
- David WilliamsManchester$345
- Lionel PereiraManchester$312
- Rose EhretManchester$254
- Kirija KokulanathanManchester$231
- John MillerExeter$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.